Austin, TX—The American Botanical Council (ABC) announced in a press release that Neem Biotech has adopted garlic and artichoke through ABC’s Adopt-an-Herb program, helping ABC keep its HerbMedPro database updated with the latest scientific and clinical research on these ingredients.
The earliest known written record of garlic as a medicine comes from an Egyption medical document dated to circa 1550 BCE, according to the press release, when it was apparently used as a treatment for circulatory ailments, malaise, and parasites. It is mentioned in the Bible, the Talmud, and in writings from Greek physicians Hippocrates and Dioscorides.
Artichoke is native to the Mediterranean area and northern Africa, the press release says. Its earliest known use was noted in writings from Greek botanist Theophrastus (371-287 BCE), who recommended it for intestinal distress. Other traditional uses focus on liver health and digestive health.
Neem Biotech is a Wales-based biotechnology company looking to enhance the life expectancy and the quality of life of patients through the use of novel, non-traditional treatments created using bioactive compounds from plants.
Graham Dixon, CEO of Neem Biotech, said in the release: “Neem is pleased that its legacy interest in garlic and artichoke is being continued through the American Botanical Council’s Adopt-An-Herb program to help people live healthier lives through the responsible use of herbs and medicinal plants.”
Mark Blumenthal, founder and executive director of ABC, said in the release: “ABC is deeply grateful to Neem Biotech for its generous adoptions of these two important medicinal herbs on ABC’s HerbMedPro database. Garlic has been one of the most popular herbal dietary supplements in the United States for more than 20 years and is used for a wide variety of clinically documented health benefits, while artichoke extracts are popular in Europe, where they are employed as an aid for various digestive conditions.”